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Abstract 
 Preeclampsia is a hypertensive disease of pregnant women that is known to cause 
detrimental physiological complications to both the mother and fetus. The hypertension 
hypothesized to result from endothelial dysfunction may be improved therapeutically by 
increasing Vascular Endothelial Growth Factor ligand concentration and it’s Vascular 
Endothelial Growth Factor Receptor 2 (VEGF and VEGFR2). Together, this receptor 
pathway may help overall vasodilation of key blood vessels linking the mother and fetal 
placental unit, allowing for increased clinical pathologies of both. Previous studies have 
also linked increased reactive oxygen species (ROS) production in preeclamptic 
pregnancies to the damaged endothelial tissues of the placenta. This specific investigation 
will use RUPP model to measure the effect of increased VEGF and VEGFR2 expression 
on ROS production in placental tissues, measured using lucigenin-enhanced 
chemiluminescence (LECL). These results may help further characterize ROS role in 
hypertensive pregnancies physiological demise, and help indicate whether VEGFR may 
serve as a potential therapeutic in treating preeclampsia.  
 
Introduction 
The hypertensive disease of pregnancy known as preeclampsia is responsible for 
morbidity, perinatal death and preterm deliveries worldwide (Uzan et. al, 2011). The 
clinical signature of preeclampsia includes edema, renal dysfunction, and fetal growth 
restriction (Facemire, 2009). It has been hypothesized that the observed hypertension 
results ultimately from endothelial cell dysfunction. This dysfunction induces damaging 
vascular changes such as decreased vasodilation, increased vasoconstriction and 
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vasospasms (Crews et. al, 2000). Decreased blood flow to the fetal placental unit arises 
from the renal and cardiovascular changes known to be associated with the disease. 
Vascular dysfunction and nutrient deficiencies often occur from the positive feedback 
loop (Maynard, 2008). Oxidative stress may also arise as a result of any of the observed 
defects. 
VEGF and VEGFR2 are thought to play a significant role in vascular 
homeostasis. As a vasodilator, the ligand VEGF binds VEGFR2 and potentially activates 
endothelial nitric oxide synthase (NOS) (Crews et. al, 2000).  Together, the two perform 
significant roles in uterine remodeling, vasodilation and placental development 
(Facemire, 2009).  
In this study, the surgical Reduced Uterine Perfusion Pressure (RUPP) pregnant 
rat model is used because of its similarities in utero-placental under-perfusion of 
preeclampsia in humans. The RUPP model has replicated the maternal hypertension, 
vascular dysfunction and fetal demise commonly observed in the preeclamptic pathology 
of humans in a previous investigation (Reho et. al, 2011).  After two weeks of gestation, a 
surgical procedure is performed to diminish uterine blood flow approximately 40%. 
Specifically, small clips are clamped around the abdominal aorta and the uterine-ovarian 
arteries (Crews et. al, 2000). This decreased blood flow causes the decreased uterine 
perfusion, and therefore deprives the fetus of a sufficient blood volume. This cascade 
adds to the maternal hypertension, as the mother’s physiology must then work harder to 
provide the fetal-placenta with sufficient blood, oxygen and nutrients (Crews et. al, 
2000). 
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 Oxidative stress has previously been investigated for 
its role in the pathophysiology of preeclampsia.  Production 
of free radicals could impact pregnancy by altering the 
normal growth and function of the placental unit (Burton, 
2009). Free oxygen radicals have the potential to oxidize 
fatty acids in lipids and amino acids in proteins, damaging 
cells and causing overall organ dysfunction (Sies, 1985). 
Potential cell ROS are seen in Figure 1. Increased oxidative 
stress in hypertensive pregnancies is thought to play a 
major hand in the initiation of degenerative preeclamptic 
physiology because of the ROS damage to the endothelium 
of placenta (Draganovic, 2016).  
Dr. Ramirez’s lab has demonstrated that vasoconstriction occurred as a result of 
increased oxidative stress in RUPP models while investigating the effects of ascorbic 
acid, a compound with antioxidant properties (Ramirez et. al, 2011). The aim of the 
overall project is to examine whether overexpression of VEGFR2 improves the utero-
placental blood flow and the maternal and fetal clinical pathologies. The experimental 
schematic can be seen in Figure 2. Placental tissues have been suggested in a previous 
study to contribute to the overproduction VEGFR; therefore contributing to the overall 
excessive vascular permeability observed in preeclamptic physiology (Grummer, 2009). 
Decreased perfusion via altered vascular reactivity may confer placental oxidative stress 
in the RUPP model. The specific aim of this branch of the investigation is analyzing ROS 
production in RUPP model placentas with and without increased VEGFR2 expression.  
Figure 1: Example reactive  
oxygen species. Created 
using ChemDraw 
Professional, Version 16.0, 
PerkinElmer Informatics.  
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↑ VEGFR2 
⇓  
↑ NO 
⇓  
↑ Vascular Relaxation 
⇓  
↑ Placental Perfusion 
⇙        ⇘ 
Maternal: 
↓Maternal hypertension 
Restore phenotype small arteries 
↑Uterine artery blood flow 
↓ Oxidative stress 
Fetal: 
↑Placental insufficiency 
Reverse growth restriction 
↓Fetal morbidity 
 
Figure 2: The approach to investigate the mechanism of VEGF signaling by selectively overexpressing 
VEGFR2 in the treated RUPP model.  
 
ROS production will be used as an indicator of overall pathology. A decrease may 
be linked to clinical improvement or impairment of the receptor expression. To measure 
the levels of oxidative stress in the rat’s placental tissues, a luminometer will be used. 
This tool will measure the emission of light from the chemical reaction between lucigenin 
(bis-N-methylacridinium nitrate) and superoxides present in the placental homogenate. 
LECL serves as one of the most convenient and sensitive approaches for ROS detection 
(Yamazaki, 2011). Using this method, superoxides can be quantitatively monitored by the 
luminometer by collecting reactive light units (RLU) produced by the reaction of 
superoxide with lucigenin (Yamazaki, 2011). A detailed depiction of the chemical 
reaction of lucigenin with a superoxide is seen in Figure 3.  
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Figure 3: Hypothesized reactions undergone in luminometer between lucigenin and a superoxide in order 
to generate chemiluminescence (Lu, 2006).  NMA* = NMA + photon. Created using ChemDraw 
Professional, Version 16.0, PerkinElmer Informatics. 
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Upon interaction with the superoxide, the lucigenin will undergo a single electron 
reduction, forming a cation radical. The radical quickly binds to the superoxide, yielding 
lucigenin dioxetane as a brief intermediate. Lucigenin dioxetane undergoes an internal 
rearrangement, creating a N-methylacridone (NMA) molecule, and a NMA radical ion 
(NMA*) (Lu, 2006). Chemiluminescence occurs as a result of NMA* relaxing from its 
excited state, returning to the ground state where it emits light at 470 nm. This relaxation 
is then detected and interpreted by the luminometer as RLU’s (Vásquez-Vivar, 1997).  
 A baseline with no homogenate sample will be run for control, and a superoxide 
baseline with lucigenin and a homogenate sample is run for comparison to the treated 
groups, treated with NADPH oxidase and tiron respectively.  
NADPH oxidase is a flavoprotein that enzymatically facilitates the single electron 
reduction of oxygen while using NADPH is oxidized to complete the redox reaction. The 
end product is a superoxide anion. The NADPH oxidase 
has previously been suggested as a major source of cellular 
superoxides in rabbit vascular tissues (Vásquez-Vivar, 
1997). Therefore, we would expect the NADPH treated 
sample to cause a spike in superoxides, and therefore 
increased RLU’s collected by the luminometer. Tiron, who’s 
chemical structure can be seen in Figure 4, has a radical 
scavenging mechanism that is hypothesized to occur by ROS 
via direct oxidation (Taiwo, 2008). Upon oxidation, the 
reduced Tiron molecule will create a hydroquinone. 
Figure 4: Chemical structure of 
Tiron, a superoxide radical 
scavenger. Created using 
ChemDraw Professional, 
Version 16.0, PerkinElmer 
Informatics. 
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Therefore, we expect a decrease in lucigenin chemiluminescence in the Tiron-treated 
sample (Münzel, 1995). Three different experimental groups were proposed to be 
analyzed using luminometer technology- SHAM, RUPP and RUPP treated with the 
nanoparticles. We hypothesize that overexpression of VEGFR2 will increase blood flow 
in the maternal-placental unit, and thus lower oxidative stress. If this holds true, then we 
should see decreased oxidative stress signals in our data collected from the treated RUPP 
model (Grummer, 2009). 
 
Materials and Methods 
Animal Maintenance 
All animal studies were approved by IACUC at the University of Akron .The rats 
used in the investigation were handled and housed in the vivarium of the University of 
Akron. Two lab technicians and one trained medical veterinarian handled the animals on 
a daily basis. The animals were observed for illness and any adverse effects from 
experimental treatments. Records of their health were logged twice a week. Medical 
documentation was updated and available on each of the rat’s cage card when in the lab. 
Standard Operating Procedures from the IACUC were followed in all aspects. 
 
Buffer Preparation 
1 L of 10X HEPES buffer was first prepared using 83 g of NaCl, 3.50 g of KCl, 
1.60 g of KH2PO4, 2.88 g of MgSO4*7H2O, 3.68 g of CaCl2*2H2O, and 23.83 g of 
HEPES. The buffer was brought to pH 7.37 by using 1 M NaOH. 10X HEPES was then 
diluted with DI water tenfold to make 1X HEPES followed by the addition of 0.5 g of 
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glucose and the pH was checked again. Before incorporation into lucigenin assay 
samples, 1X HEPES was heated for ten minutes at 37 C, re-evaluated and the pH was 
adjusted to 7.37 again to ensure it as optimal physiological comparison. The pH was 
measured over the course of experiments to ensure it remained stable. 10X HEPES was 
stored for several weeks, however 1X HEPES was freshly prepared before each use. 
 
Preparation of protein samples 
Placental tissues were isolated from frozen rat placenta collected six-ten months 
prior to experimentation. Each sample was homogenized prior to the measurement of 
protein concentration by Bradford Assay. The preparation entailed collecting ~0.3 g 
tissue and adding 1X HEPES buffer (pH ~7.37) at 0.1 g/mL. An example can be seen in 
Sample Calculation 1. 
 
𝑡𝑖𝑠𝑠𝑢𝑒 𝑤𝑒𝑖𝑔ℎ𝑡 = 0.327 𝑔 
0.327 𝑔
0.1
= 3.27 𝑚𝐿 
3.27 𝑚𝐿 −  0.327 𝑚𝐿 = 2.943 𝑚𝐿 1𝑋 𝐻𝐸𝑃𝐸𝑆 𝑏𝑢𝑓𝑓𝑒𝑟 𝑛𝑒𝑒𝑑𝑒𝑑 
Sample Calculation 1: Above is an example of the equations used to find the appropriate buffer volume 
needed to make the homogenate.  
 
The protein solution was kept on ice for the remainder of preparation. 
Approximately 50 μL of protease inhibitor (100x) was added before homogenizing until 
smooth liquid was observed. Homogenate was then spun in an IEC Centra CL2 
centrifuge at 3000 RPM for six-eight minutes. The protein supernatant was collected and 
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the cell pellet was disposed. Protein was stored at -80 C until assayed. SHAM placenta 
was used to create the first set of data. RUPP placenta without treatment of VEGF was to 
be used the second time, while RUPP placenta treated with VEGF was to be used for the 
final data set. 
 
Measurement of Protein Concentration in Placental Homogenate Samples 
A standard Bradford assay purchased from Sigma was run each day tissues were 
assayed to generate a standard curve. This curve was used to find the protein 
concentration in each of the homogenate samples analyzed based on their recorded 
absorbance. The amount of protein present in each sample is relative to the amount of 
RLU’s measured using the lucigenin assay. Six standard samples were prepared, with a 
total volume of 3000 μL, and measured in a Spectrometer at 595 nm.  
The first sample contained (0 μL BSA + 2400 μL DI water + 600 μL Bradford 
Reagent). The second sample contained (3.9 μL BSA + 2397 μL DI water + 600 μL 
Bradford Reagent). The third sample contained (7.5 μL BSA + 2391μL DI water + 600 
μL Bradford Reagent). The fourth sample contained (15 μL BSA + 2385 μL DI water + 
600 μL Bradford Reagent). The fifth sample contained (22.5 μL BSA + 2376 μL DI 
water + 600 μL Bradford Reagent). The sixth sample contained (30 μL BSA + 2370 μL 
DI water + 600 μL Bradford Reagent).  Four placental samples were prepared with (200 
μL HMG + 1800 μL DI + 600 μL Bradford) and measured as well. Their measurements 
can be seen in Table 1. The absorbance measurements from four representative protein 
samples were averaged and plotted on the standard curve, seen in Figure 5. R2 values 
were obtained to ensure standards accuracy. 
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Measurement of ROS Production 
The lucigenin assay was used to measure chemiluminesence exhibited by 
superoxides formed via NADPH oxidase, and to confirm specificity by the ROS 
scavenger, Tiron. The protocol for the Turner Biosystems luminometer called for the use 
of lucigenin at 100 μmol/L. Once properly diluted, the lucigenin stock was covered in foil 
when being stored in the freezer, and was carefully added to samples in a dark room to 
prevent interaction with light waves. Once in the samples, each bullet tube that contained 
lucigenin was covered in foil in order to prevent potential light wave interaction.  Before 
use, the pH of 1X HEPES buffer was adjusted to 7.37, incubated at 37 C for ten minutes, 
then re-examined to ensure proper pH prior to the beginning of the analysis.  A baseline 
sample was prepared with (400 μL 1X HEPES buffer + 0.6 μL lucigenin) before being 
placed in luminometer. Fifteen RLU collections were taken. Ideally, this should reflect 
the lowest value because no homogenate or protein was present in the sample. 
A superoxide baseline sample was prepared with (100 μL HMG + 400 μL 1X 
HEPES buffer + 0.6 μL lucigenin). The sample was incubated in the water bath for three 
minutes at 37 C. A stimulated superoxide sample was prepared using 10mM NADPH 
(100 μL HMG + 400 μL 1X HEPES buffer + 0.6 μL lucigenin + 10 μL of 10 mM 
NADPH), and incubated in a water bath at 37 C for three minutes. The addition of 
NADPH was to produce ROS in an NADPH oxidase-dependent manor, causing a spike 
in the signal detected in this sample. After preparation, the bullet tube was placed in the 
luminometer and fifteen RLU collections were taken. 
A final sample was prepared with 100 μM/L Tiron (100 μL HMG + 400 μL 1X 
HEPES buffer + 0.6μL lucigenin + 50 μL Tiron) and incubated in a water bath at 37 C 
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for three minutes. After incubation, the bullet tube was placed in the luminometer and 
fifteen RLU’s were collected. 
The parameters of the luminometer were preset to the lucigenin protocol. Reactive 
light unit (RLU) measurements for each sample were taken constantly every five seconds 
until fifteen measurements were recorded. 
 
Statistics 
In order to normalize the data, the RLU’s were to be divided by the concentration 
of protein found in the homogenate sample used during that particular trial. This data 
could then be used in a T-test and ANOVA to compare ROS measurements between 
experimental groups. 
 
Results and Discussion 
 In order to standardize our luminometer measurements, we first normalized our 
protein concentrations for each of our placental samples. The measurements can be seen 
in Table 1.  
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Table 1: Absorbance values for standards used in the Bradford assay.  
Absorbance’s Collected to Generate Standard Curve 
μL in Assay μg in assay Abs (595nm) 
Standard Samples 
3000 0 0 
3000 390 0.046 
3000 750 0.09 
3000 1500 0.148 
3000 2250 0.217 
3000 3000 0.261 
Unknown Samples 
2600 61.44 0.566 
2600 56.78 0.524 
2600 61.00 0.562 
2600 61.33 0.565 
Average protein concentration 60.14  
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Figure 5: Standard curve developed using six standards and the Bradford Assay protocol. Absorbances 
were recorded at 595 nm, and the linear fit equation generated was used to find the protein concentrations 
of the four homogenate tissue samples. The R2 value indicates a relatively linear fit, making it a suitable 
equation to find protein concentrations of unknown samples. 
 
 The standard curve was corrected with an absorbance reading of 0 for a protein 
concentration of 0. The linear fit equation 𝑦 = 9 ∗ 10−5𝑥 + 0.013 (y = mx + b) was used 
to find the unknown samples protein concentrations. The absorbances at 595 nm were 
plugged in for y, and solved for x in order to find protein concentration in the sample. 
The corresponding arithmetic can be seen in Sample Calculation 2. Four homogenate 
samples were made so their protein concentrations could be averaged, yielding an 
average protein concentration of 60.14 μg/μL.  
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𝑦 = 9 ∗ 10−5𝑥 + 0.013 
0.566 = 9 ∗ 10−5𝑥 + 0.013 
𝑥 = 6144.44 𝑢𝑔/𝑚𝐿 
6144.44 𝓊𝑔
𝑚𝐿
∗ 10 =
61444.4 𝓊𝑔
𝑚𝐿
= 61.44 𝓊𝑔/𝓊𝐿 
Sample Calculation 2: Linear equation used to find protein concentrations of unknown placental tissues, 
created by the standard curve seen in Figure 5. Because the homogenate samples were diluted 10 fold, this 
had to be factored into the final protein calculation. 
 
Once the protein concentrations were found, the homogenate samples were taken 
to the luminometer to measure RLUs. Fifteen data points were collected for each of the 
four experimental conditions, using two different protein samples. The normalized data is 
shown in Figure 6. 
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Figure 6: Measurement of superoxide levels in placental tissue isolated from SHAM animals. Data was 
normalized by dividing RLU signal strength by concentration of protein found within the sample. The 
baseline was developed using a chemiluminesence assay and compared to a positive control (superoxide 
baseline). The NADPH-treated samples were stimulated to produce ROS and spike RLU production, while 
the Tiron-treated samples were meant to scavenge the superoxide anions, decreasing RLU signal.  
 
At this point, only SHAM placental tissues were tested and not the VEGF 
experimental groups. Each of the two samples tested in the luminometer were collected 
from SHAM placental tissues. The fifteen replicate measurements for each condition 
were averaged and later normalized by dividing them by the protein concentration found 
in that particular sample. This allowed for the comparison of both SHAM samples, 
despite their differences in protein concentration. The baseline sample was meant to act 
as a control to compare to the superoxide baseline that contained the homogenate sample. 
The baseline should have the lowest lucigenin stimulation because it contained no 
homogenate, and therefore we would expect the superoxide baseline to have higher RLU 
signal. Although the sample 1 superoxide baseline appeared to have a higher signal than 
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the baseline, the error bars demonstrate there was no significant difference between the 
superoxide baseline and lucigenin baseline. Both NADPH-stimulated samples showed an 
increase in RLU production, as predicted. Similarly, the data reflect that the Tiron did act 
as a superoxide scavenger, seeking out ROS and preventing the lucigenin from 
interacting with the free electrons. This led to an overall decrease in RLU production in 
comparison to the NADPH treated samples.  
 
Conclusion 
  The detrimental capability of oxidative stress in hypertensive pregnancies has 
been an important topic of study to medical professionals worldwide (Draganovic, 2016). 
This investigation was meant to test the oxidative stress levels between three 
experimental groups- SHAM, RUPP, and RUPP models with increased VEGFR2 
expression. Both RUPP models represented preeclamptic pathology (Reho et al., 2011). 
RUPP treated with LTP nanoparticles were hypothesized to increase VEGFR2 
expression. The SHAM models were used as a control to compare ROS levels of normal 
pregnant rats with those in a hypertensive state (Reho et al., 2011).   
We would predict that the RUPP models would exhibit higher levels of oxidative 
stress due to the decreased uterine perfusion, vasoconstriction and hypertensive 
physiology when compared to the untreated SHAM models (Ramirez, 2015). Treatment 
of LTP nanoparticles was meant to increase VEGFR2 expression. Decreased VEGFR2 
expression is linked to preeclampsia pathology (Grummer, 2009). Treatment of rat’s 
experimental preeclampsia is predicted to increase VEGF signaling and enhance the 
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overall uterine perfusion. We would expect to see a decrease in oxidative stress when 
analyzing these tissues samples (Grummer, 2009).  
During the time of writing, the experiment was still continuing. Only data 
collected from the SHAM group was recorded to this point, and some difficulties were 
experienced in the process. Only two protein samples produced adequate RLU 
measurements, because for all other samples the baselines did not generate accurate 
measurements. Without proper baseline measurements, no valid comparisons could be 
made to the experimental samples. Several obstacles prevented the collection of multiple 
adequate data sets, including the failure to ensure proper pH before testing for ROS by 
the luminometer. Improper pH may have denatured the protein samples before processing 
in the luminometer. In an attempt to correct this problem, all homogenate samples and 
buffers were re-made, ensuring proper pH every step of the way before testing the entire 
experimental sample. Unfortunately, this did not seem to correct the inaccurate baseline 
readings obtained. A new lucigenin sample was ordered and the stock was re-made to 
correct any discrepancies that may have come from it, as it is a very light-sensitive 
chemical and could have been another cause of the inaccurate baselines. Even with fresh 
lucigenin reagent, RLU readings were still not as predicted. In addition, the Turner 
Biosystems luminometer may have been responsible for inaccurate RLU measurements, 
as it had not been calibrated since our use in the experiment.  
Although there were two SHAM homogenate samples that aligned with what was 
predicted to happen, there was not enough significant evidence to support our hypothesis 
at this time. More SHAM samples should be analyzed, and the other experimental groups 
should be tested as well to draw accurate conclusions from the total data. Further 
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investigation the cross-talk between VEGF signaling and ROS production could help find 
potential pharmaceuticals and therapeutics to combat preeclampsia, bettering the lives of 
the mother and the fetus.  
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Safety Appendix 
Dr. Ramirez and his graduate students taught safety training. The use of Personal 
Protective Equipment was used to minimize risk of injury while dealing with chemicals. 
Lab gloves and safety glasses also reduced risk of incidence. Appropriate LUC-0-ING 
protocol was followed when using the luminometer in reference to the Turner Biosystems 
manual. Salts for making HEPES buffer were handled with care, and cautious handling of 
the 1 M NaOH was used when pHing the buffer. pH waste was dumped in a specified 
container and excess buffer was diluted and disposed of down the drain. No injuries or 
major spills occurred in the laboratory. 
 
